Clinical Trials for HuidaGene Therapeutics

Explore 7 clinical trials worldwide

Showing 1-7 of 7 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: HuidaGene Therapeutics

Clinical Trials (7)

NCT07063251
An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
EARLY_PHASE1Recruiting
6 participants
Started: Aug 20, 2025 · Completed: Feb 28, 2028
1 condition1 sponsor1 location
NCT06623279
Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial
PHASE1Not yet recruiting
15 participants
Started: Apr 1, 2025 · Completed: Feb 1, 2031
1 condition1 sponsor0 locations
NCT06594094
An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)
NARecruiting
6 participants
Started: Nov 6, 2024 · Completed: Sep 30, 2026
1 condition1 sponsor1 location
NCT06615206
A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)
NARecruiting
6 participants
Started: Oct 30, 2024 · Completed: Oct 31, 2026
1 condition2 sponsors1 location
NCT05906953
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
PHASE1/PHASE2Recruiting
20 participants
Started: Oct 31, 2023 · Completed: Dec 31, 2025
2 conditions1 sponsor3 locations
NCT06031727
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
EARLY_PHASE1Recruiting
12 participants
Started: Sep 4, 2023 · Completed: Jun 30, 2026
1 condition3 sponsors2 locations
NCT06088992
Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)
EARLY_PHASE1Active, not recruiting
9 participants
Started: Jan 10, 2023 · Completed: Oct 30, 2028
1 condition2 sponsors1 location